Cerevance Ltd.
Cerevance is developing therapeutics that act on target proteins expressed highly selectively in brain cell types that die in disease, play a key role in the disease process, or are located in brain circuits disrupted by disease. In some cases, our NETSseq platform has revealed that a target protein is dysregulated in human disease tissue samples. We believe that advancing drugs that act on selectively expressed targets will enable us to deliver more effective medicines that slow disease progression or provide symptomatic relief while causing fewer “on-target” side effects.
